×
About 3,278 results

ALLMedicine™ Anaplastic Large Cell Lymphoma Center

Research & Reviews  969 results

Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or ...
https://doi.org/10.1007/s12325-023-02470-9
Advances in Therapy; Elsea D, Savage KJ et. al.

Mar 16th, 2023 - Brentuximab vedotin versus physician's choice of methotrexate (MTX) or bexarotene (BEX) significantly improved progression-free survival (PFS) (median PFS, 16.7 vs. 3.5 months) and delayed time to subsequent treatment (8.4 vs. 3.7 months), with si...

Diagnosis and management of rare paediatric Non-Hodgkin lymphoma.
https://doi.org/10.1016/j.beha.2023.101440
Best Practice & Research. Clinical Haematology; Xavier AC, Suzuki R et. al.

Mar 13th, 2023 - Mature B-cell lymphomas, (B- or T-cell) lymphoblastic lymphomas (LBL), and anaplastic large cell lymphoma (ALCL) correspond to about 90% of all non-Hodgkin lymphoma (NHL) cases occurring in children and adolescents. The remaining 10% encompass a c...

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and...
https://doi.org/10.1016/j.beha.2023.101444
Best Practice & Research. Clinical Haematology; Rigaud C, Knörr F et. al.

Mar 13th, 2023 - Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is a CD30-positive T cell lymphoma characterized by signalling from constitutively activated ALK fusion proteins. Most children and adolescents present in advanced sta...

Diagnosis and management of cutaneous lymphomas and lymphoid proliferations in children...
https://doi.org/10.1016/j.beha.2023.101448
Best Practice & Research. Clinical Haematology; Stokke J, Tann A et. al.

Mar 13th, 2023 - Cutaneous lymphomas and lymphoid proliferations (LPD) in children, adolescents, and young adults (CAYA) are a heterogeneous group of lymphoid neoplasms that present formidable diagnostic challenges to clinicians and pathologists alike. Although ra...

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Mar 10th, 2023 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...

see more →

Guidelines  6 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic La...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894347
British Journal of Haematology; Turton P, El-Sharkawi D et. al.

Nov 23rd, 2020 - Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast sy...

American Registry of Pathology Expert Opinions: Recommendations for the diagnostic work...
https://doi.org/10.1016/j.anndiagpath.2020.151623
Annals of Diagnostic Pathology; Vega F, Amador C et. al.

Sep 19th, 2020 - The diagnosis of T-cell lymphomas is highly challenging and requires an integrated approach in which clinical, morphologic, immunophenotypic and molecular data are incorporated into the diagnosis. Under the auspices of the American Registry of Pat...

Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anap...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106983
Journal of Clinical Oncology : Official Journal of the Am... Jaffe ES, Ashar BS et. al.

Feb 12th, 2020 - To provide guidelines for the accurate pathologic diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the preoperative evaluation of the patient with suspected BIA-ALCL, and the pathologic evaluation of the capsulecto...

NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated...
https://doi.org/10.1093/asj/sjw259
Aesthetic Surgery Journal; Clemens MW, Horwitz SM

Feb 12th, 2017 - Published case series demonstrate a lack of treatment standardization for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) with a wide variety of therapeutic strategies being employed at all stages of disease. The National Compr...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  78 results

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01979536

Mar 10th, 2023 - PRIMARY OBJECTIVES: I. To determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (anaplastic large cell lymphoma [ALCL]99) and to determine the tolerability of crizotinib given in combination with chemoth...

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT04447027

Mar 9th, 2023 - Background: Mature T-cell malignancies (TCM) are rare and heterogeneous group of leukemias and lymphomas accounting for 5 to 10% of all lymphomas in the US Patients with systemic TCM are most commonly treated with a CHOP (cyclophosphamide, doxorub...

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
https://clinicaltrials.gov/ct2/show/NCT04094610

Mar 9th, 2023 - Enrollment of subjects into Phase 1 will proceed concurrently by age as follows: Subjects <12 years old will initially be enrolled in the Phase 1 part to determine the pediatric RP2D for this age group; once the pediatric RP2D is determined, subje...

Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"
https://clinicaltrials.gov/ct2/show/NCT04213209

Feb 13th, 2023 - The drug being tested in this survey is called Brentuximab Vedotin intravenous infusion 50 mg. This intravenous infusion is being tested to treat adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding...

Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture
https://clinicaltrials.gov/ct2/show/NCT05017337

Jan 19th, 2023 - BASILICA is a translational research study being undertaken at The Royal Marsden NHS Foundation Trust that aims to investigate aetiology of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), capsular contracture (CC) as well as t...

see more →

News  252 results

Breast cancer: Postmastectomy implant reconstruction increases risk for anaplastic large cell lymphoma
https://www.mdedge.com/hematology-oncology/article/260233/breast-cancer/breast-cancer-postmastectomy-implant-reconstruction

Dec 19th, 2022 - Key clinical point: The relative risk for anaplastic large cell lymphoma (ALCL) was significantly increased in women who underwent implant reconstruction after mastectomy for breast cancer (BC) or ductal carcinoma in situ. Major finding: The relat.

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
https://www.onclive.com/view/fda-grants-fast-track-designation-to-mt-101-for-cd5-relapsed-refractory-ptcl

Nov 21st, 2022 - The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma (PTCL), according to an announcement from Myeloid Therapeutics, Inc.1...

From B to T: a Case of Concurrent B-Cell and T-Cell Lymphomas Successfully Palliated With Targeted Therapies
https://www.mdedge.com/fedprac/avaho/article/257685/lymphoma-plasma-cell-disorders/b-t-case-concurrent-b-cell-and-t-cell
John Esther, Shashank Sama et. al.

Sep 9th, 2022 - Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive type of non- Hodgkin lymphoma (NHL), comprising 30% of all NHL. Due to a decreased state of immunosurveillance resulting from the disease itself and its associated ther.

Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL
https://www.onclive.com/view/tolinapant-displays-encouraging-activity-and-safety-in-relapsed-refractory-ptcl-ctcl

Aug 31st, 2022 - Single-agent tolinapant (ASTX660) generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), according to data from the phase 2 A...

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma
https://www.onclive.com/view/brentuximab-vedotin-boosts-survival-in-adult-and-aya-patients-with-advanced-hodgkin-lymphoma

Jul 21st, 2022 - Findings from recent studies have demonstrated the value of brentuximab vedotin (Adcetris) in both adult and adolescent and young adult (AYA) patients with advanced Hodgkin lymphoma, Ann S. LaCasce, MD, MMSC, said during a presentation at the 2022...

see more →

Patient Education  3 results see all →